The history behind the discovery, research, and treatment of hemophilia is as complex and intriguing as the disease itself. A ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Haemophilia / Hemophilia symptoms and diagnosis: ... A sample of placenta is removed from the uterus and tested. This test is known as a CVS (chorionic villus sampling) test.

Hemophilia A is a condition that affects the ability of the blood to clot, which leads to prolonged bleeding in response to injury. ... for example. Sources.

Still, medications to treat hemophilia on average cost more than $270,000 annually per patient, according to a 2015 Express Scripts report, and they can easily soar past $1 million annually.

For example, there are just 1,200 to 1,600 patients with CLN2 disease, a type of Batten disease, in territories where BioMarin operates around the world who are eligible to take their drug.

Do lower levels of factor VIII and factor IX in hemophilia have a protective effect against the risk of thrombotic events and CVD? A new study has some surprising answers.

Hemophilia B is a rare X-chromosome-linked bleeding disorder caused by mutations in ... “The results of this important study are a perfect example of how UCL research and innovation can ...

In the hemophilia example, he said, a company might have to demonstrate, after a product is on the market, that it actually does reduce bleeding.

Mild hemophilia is defined as a Factor VIII level of between 5% and 25%, with bleeding episodes only occurring in response to severe trauma or surgery, for example.